Hemispherx Biopharma Revenue and Competitors

Ocala, FL USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Hemispherx Biopharma's estimated annual revenue is currently $11.3M per year.(i)
  • Hemispherx Biopharma's estimated revenue per employee is $201,000

Employee Data

  • Hemispherx Biopharma has 56 Employees.(i)
  • Hemispherx Biopharma grew their employee count by 4% last year.

Hemispherx Biopharma's People

NameTitleEmail/Phone
1
Associate Director AdministrationReveal Email/Phone
2
Clinical Research AssociateReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$26.5M132N/AN/AN/A
#2
$10.1M5014%N/AN/A
#3
$282.6M1406N/AN/AN/A
#4
$13.9M6944%N/AN/A
#5
$11.3M564%N/AN/A
#6
$11.5M57-7%N/AN/A
#7
$211.7M10724%N/AN/A
#8
$24.1M1205%N/AN/A
#9
$7.8M39-2%N/AN/A
#10
$12.9M64-2%N/AN/A
Add Company

What Is Hemispherx Biopharma?

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental therapeutics Ampligen®. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx’s platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because Ampligen® is experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials. The FDA approval of Alferon N Injection® is limited to the treatment of refractory or recurrent external genital warts in patients 18 years of age or older. The Company’s Alferon® N approval in Argentina includes the use of Alferon N Injection® (under the brand name “Naturaferon”) for use in any patients who fail, or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection. The Company exclusively operates a GMP certified manufacturing facility in the United States for commercial products.

keywords:N/A

N/A

Total Funding

56

Number of Employees

$11.3M

Revenue (est)

4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$16.5M5610%N/A
#2
N/A5812%N/A
#3
$7.6M60N/AN/A
#4
$3.5M635%N/A
#5
$12.9M63-9%N/A